» Articles » PMID: 20009140

De-novo Cholangiocarcinoma in Native Common Bile Duct Remnant Following OLT for Primary Sclerosing Cholangitis

Overview
Journal Ann Hepatol
Specialty Gastroenterology
Date 2009 Dec 17
PMID 20009140
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Primary sclerosing cholangitis (PSC) is a chronic, progressive, inflammatory and obstructive disease of the intra- and extra-hepatic bile ducts of unknown etiology. Currently, orthotopic liver transplantation (OLT) is the only definitive treatment for PSC-related end-stage liver disease. However, PSC has been known to recur in the grafted liver. Roux-en-Y hepaticojejunostomy is more commonly performed than choledochocholedochostomy for PSC, although choledochocholedochostomy has been found to be safe and efficacious for PSC if the distal common bile duct is uninvolved at the time of OLT. Our case is unique in that it describes a patient who developed de-novo cholangiocarcinoma in the remnant portion of the native common bile duct six years after OLT with choledochocholedochostomy for PSC-associated end-stage liver disease without having PSC recurrence. In conclusion, our case report indicates that choledochocholedochostomy may not be desirable in PSC due to an increased risk of developing cholangiocarcinoma in the native common bile duct. This risk exists as well with a Roux-en-Y hepaticojejunostomy in the remaining intra-duodenal and intra-pancreatic biliary epithelium, although in theory to a lesser extent. Therefore, the risk of developing cholangiocarcinoma in the recipient common bile duct can only be completely eliminated by performing a Whipple procedure at the time of OLT.

Citing Articles

Review of incidence and outcomes of treatment of cholangiocarcinoma in patients with primary sclerosing cholangitis.

Saffioti F, Mavroeidis V World J Gastrointest Oncol. 2021; 13(10):1336-1366.

PMID: 34721770 PMC: 8529934. DOI: 10.4251/wjgo.v13.i10.1336.


Biliary endoscopy in the management of primary sclerosing cholangitis and its complications.

Fung B, Tabibian J Liver Res. 2019; 3(2):106-117.

PMID: 31341699 PMC: 6656407. DOI: 10.1016/j.livres.2019.03.004.


Cancer risk in primary sclerosing cholangitis: Epidemiology, prevention, and surveillance strategies.

Fung B, Lindor K, Tabibian J World J Gastroenterol. 2019; 25(6):659-671.

PMID: 30783370 PMC: 6378537. DOI: 10.3748/wjg.v25.i6.659.


Primary Sclerosing Cholangitis, Part 2: Cancer Risk, Prevention, and Surveillance.

Tabibian J, Ali A, Lindor K Gastroenterol Hepatol (N Y). 2018; 14(7):427-432.

PMID: 30166959 PMC: 6111497.


Primary sclerosing cholangitis: A review and update.

Tabibian J, Bowlus C Liver Res. 2018; 1(4):221-230.

PMID: 29977644 PMC: 6028044. DOI: 10.1016/j.livres.2017.12.002.